Fate Therapeutics, Inc. (NASDAQ:FATE)’s earnings is on the doorstep as the firm is set to report on 8/14/2017 4:30:00 PM. For the last period, the company reported quarter over quarter EPS growth of 16.00% and quarter over quarter sales growth of -23.10%.
Heading into the earnings release, covering sell-side analysts have a consensus target price of $7.80 on Fate Therapeutics, Inc. shares. After a recent check, company stock has been trading near the $2.98 mark.
Sell-side analysts have also provided a consensus recommendation of 1.70 on company shares. Investors will be eagerly watching to see if the firm beats or misses on the earnings front.
Depending on the earnings numbers reported, Fate Therapeutics, Inc. (NASDAQ:FATE) stock may see increased volatility following the report. In terms of recent volatility, the average for the month is 7.75% and 11.59% for the past week. The relative volume (ratio between current volume and 3-month average) is presently sitting at 0.57.
Since the start of the New Year, Fate Therapeutics, Inc. (NASDAQ:FATE) shares have seen a move of 18.73%. Looking back over the last month, shares have performed -5.40%. For the past 5 days of trading, the stock has seen a move of 1.36%.
Let’s also take a brief look at the stock price in relation to some highs/lows and moving averages. Fate Therapeutics, Inc. (NASDAQ:FATE) shares have been recently spotted -47.54% away from the 52-week high, and 65.56% away from the 52-week low mark.
After a recent look, shares have been seen -12.10% from the 200-day moving average, and -3.68% from the 50-day moving average. The stock’s current RSI reading is at 51.73.
As the earnings date approaches, we can see that insider ownership is currently 24.77% shares, and institutional ownership is at 74.00% for Fate Therapeutics, Inc. (NASDAQ:FATE) stock. Over the past few months, insider ownership has seen a move of 0.00% while institutional ownership has changed 1.09%.